Chronic Spontaneous Urticaria

The first-in-class mast cell–selective c-Kit inhibitor ALY-301 enters clinical testing for cold urticaria in Germany.

The topline data support advancing INF904 into larger, controlled trials as a potential convenient alternative to injectable biologics.

Discover the latest advancements in CSU therapy, including Gil Yosipovitch's insights on barzolvolimab's promising results and its potential impact on patient care.

At Fall Clinical 2025, Marc Serota, MD, discussed how GLP-1 therapies, new CSU treatments, and hybrid care models are reshaping dermatologic practice heading into 2026.

Quality of life improvements paralleled clinical efficacy in the CUPID studies of dupilumab.

World Urticaria Day raises awareness about chronic spontaneous and inducible urticaria, highlighting treatment advancements and patient challenges.

Fewer than 20% of eligible patients currently receive injectable therapies, highlighting the need for oral alternatives.

Based on the diagnosis and treatment challenges of CSU, it’s crucial for allergists and dermatologists to work together toward an effective approach based on the latest evidence.

Discover expert insights on treating uncommon conditions like lichen planus, CSU, and polymorphous light eruption from Maui Derm NP+PA Fall 2025.

Patients switched from placebo to remibrutinib at week 24 showed similar reductions in autoantibodies by week 52.

According to a poster at the 2025 EADV Congress, barzolvolimab achieved comparable improvements in weekly Urticaria Activity Scores across immunoglobulin E (lgE) subgroups.

This review of the latest dermatologic studies highlights new research on novel image fusion for tongue SCC, persistent nodules following HA fillers, rice bran extract for wound healing, and more.

Explore the potential of dupilumab for treating omalizumab-resistant chronic spontaneous urticaria, offering new hope for affected patients.

Explore how model-informed drug development shapes ligelizumab's journey in treating chronic spontaneous urticaria, despite its eventual discontinuation.

Explore the latest strategies for managing CSU, including personalized therapies and updated 2025 guidelines for effective treatment.

EAACI's report highlights current practices and challenges in diagnosing and managing chronic urticaria in pediatric patients, emphasizing the need for improved education and resources.

Explore effective strategies for managing CSU, including tailored therapies and the latest treatment advancements for optimal patient care.

This review of the latest dermatologic studies focuses on chronic spontaneous urticaria with new research on the transition from omalizumab to dupilumab, metabolic syndrome in urticaria patients, current pediatric CSU guidelines, and more.

The randomized, placebo-controlled trial will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in up to 150 healthy volunteers.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore how synthetic data revolutionizes CSU research, enabling smaller sample sizes and enhancing trial efficiency and inclusivity.

According to a new poster, patients with chronic spontaneous urticaria seek better relief options, highlighting significant impacts on quality of life and mental well-being globally.

Discover Walter Liszewski, MD's insights on emerging therapies and consumer safety at Elevate-Derm Summer 2025, focusing on allergy research and treatment advancements.

New findings at Elevate Derm highlight remibrutinib's rapid and sustained efficacy in reducing chronic spontaneous urticaria symptoms, offering hope for patients.

Explore how genetic factors influence acute and chronic urticaria, revealing potential for personalized treatment strategies.